Immune checkpoint inhibitor-associated autoimmune encephalitis—an emerging cause for encephalitis

A woman in her 70s with stage IV lung adenocarcinoma was admitted with a 4-day history of altered mental status. She had received four cycles of pembrolizumab for the lung cancer. The last dose was given 2 weeks prior to admission. No chemotherapy was administered. On examination, she was somnolent